Clinical trial
Interleukin-7 in Treating Patients With Refractory Solid Tumors
NCT00062049 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00062049 |
|---|---|
| Title | Interleukin-7 in Treating Patients With Refractory Solid Tumors |
| Official title | A Phase I Study of Subcutaneous "CYT 99 007" (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | recombinant interleukin-7 |
| Enrollment | 30 |
| Start date | Apr 1, 2003 |
| Completion | May 1, 2011 |
| First posted | Jun 6, 2003 |
| Last update posted | Mar 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: